Medtronic inks cross license deal with Tandem Diabetes Care, as reported on 0 July 2020. 

Medtronic plc and Tandem Diabetes Care today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential legal disagreements.

With certain exclusions, this agreement applies to the companies’ existing products, as well as new products for at least the next five years, and also includes a provision not to clone one another’s products. No payments will be exchanged as part of this agreement and further terms were not disclosed.


Novel insulin sensor under development for point-of-care testing, insulin-delivery devices was published by Jill Rollet for Healio.com/endocrinology, 15 June 2020.

A wearable microneedle, multifluidic insulin-sensing device may one day allow closed-loop insulin-delivery systems to directly test insulin levels, which in turn might help increase time in range for people with type 1 diabetes.

“Up to this point in time, there has been no way to commercially measure insulin in real time,” Kelilah Wolkowicz, PhD, a postdoctoral fellow at Harvard John A. Paulson School of Engineering and Applied Sciences, said during a presentation at the virtual American Diabetes Association Scientific Sessions. “While there are techniques to perform laboratory-based insulin measurements, there is a lack of ability to obtain these measurements within a home environment, such as through point-of-care devices.  From a control perspective, our regulated variable is glucose, and while we can estimate the relationship between glucose and insulin, we still do not have a method of measuring insulin.”

Read more:  Novel insulin sensor under development

Share This